causing a viremia that typically clears within the first two weeks after symptom debut 46 (10, 29). Previous studies have described high frequencies of hantavirus-specific 47 memory CD8 T cells in previously infected individuals (21, 38) . These findings, 48 together with the absence of evidence for hantavirus persistence or symptomatic re-49 infection in humans, have suggested a role for CD8 T cells in the generation of 50 protective long-lasting immunity. However, the primary antiviral CD8 T cell response, 51 which is likely responsible for viral clearance and T cell memory formation, is not 52 well characterized in this or similar human diseases. 53
Much of our present knowledge of CD8 T cell responses to acute viral 54
infections originates from experimental model systems in which mice have been 55
infected with viruses such as lymphocytic choriomeningitis virus (LCMV) or vaccinia 56 virus (VV) (6, 11, 25) . In these model systems, infection induces rapid expansion and 57 activation of antigen-specific cells and the emergence of large numbers of activated 58 effector CD8 T cells (6, 25) . The expanding population of effector cells is highly 59 susceptible to apoptosis, and the response culminates soon after viral clearance. At 60 that point, the virus-specific CD8 T cell population contracts leaving behind long-61 lived memory cells (25) . Human antiviral CD8 T cell responses have been analyzed 62 primarily in settings of chronic infection, such as hepatitis B virus (HBV), hepatitis C 63 virus (HCV), human immunodeficiency virus 1 (HIV-1), and Epstein-Barr virus 64 (EBV) infections (19, 22, 33, 37) . In many respects, these disease settings differ from 65 those of the murine models classically used to study viral infection; the latter often 66 on October 22, 2017 by guest http://jvi.asm.org/
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Results
138
Identification of responding CD8 T cells during acute hantavirus infection in 139 humans 140
Fifteen patients with acute hantavirus infection, sampled longitudinally during the 141 acute (average days 6 and 10) and the convalescent (average day 60) stages of disease, 142 and 15 uninfected controls were included in the study. First, total lymphocyte counts 143 and numbers of CD8 as well as CD4 T cells were determined. Minor changes were 144 observed in total lymphocyte counts as well as CD8 and CD4 T cell numbers during 145 the infection (see Fig. S1 in the supplemental material). Early after infection, CD8 T 146 cells were increased in numbers in the patients compared to CD4 T cells. At day 60 147 after infection, these numbers had started to normalize to levels observed in 148 uninfected individuals (see Fig. S1 in the supplemental material). We subsequently 149 evaluated the expression of Ki67, CD38, and HLA-DR on CD8 T cells. A substantial 150 number of CD8 T cells expressed Ki67, CD38, and HLA-DR during the acute phase 151 of infection but not at day 60 after symptom debut or in the uninfected controls (Fig.  152   1A) . On average, 54%, 51%, and 30% of total CD8 T cells expressed Ki67, CD38, or 153 HLA-DR, respectively, at day 6 after symptom debut (Fig. 1B) (Fig. 1D) . To compare the kinetics of responding CD8 T cells to 163 viral burden, we quantified the viral load in all patients at multiple time-points during 164 the acute phase. The viral load peaked 5.4 days after symptom debut with, on average, 165 107 000 viral copies/ml ( Fig. 1E and data not shown) . From day 7 after symptom 166 debut, the viral load declined in all patients; at day 10 a majority of the patients had 167 no detectable virus, and no virus was found in infected patients from day 16 after 168 symptom debut and onwards (Fig 1. E and data not shown). Interestingly, the decline 169 observed in effector CD8 T cells coincided time-wise with the decline in viral load 170 and clearance of the virus from the infected patients. 171
When extending our analysis to CD4 T cells, we did not detect 172 However, both an increase in Ki67-positive cells and a trend towards higher CD38 174 expression were evident, although, no difference was apparent in HLA-DR expression 175 when comparing the acute with the convalescent phase of infection and the uninfected 176 controls (see Fig. S2A and S2B in the supplemental material). 177
These data demonstrate that the primary effector CD8 T cell response occurs 178 rapidly and vigorously, encompassing at the peak response up to 50% of all CD8 T 179 cells. Thereafter, the response decreases, paralleled by a decline in viral load and 180 clearance of viremia in the infected patients. 181
182
Responding CD8 T cells display an effector phenotype 183
From models of infection in mice and studies of CD8 T cells during chronic human 184 viral infections in humans, phenotypic profiles have been established for naïve, 185 effector and memory CD8 T cell subsets (2, 3, 33, 43, 44 patients only at days 6 and 10 after symptom debut (Fig. 1B) , consistently exhibited 191 low levels of CCR7, CD45RA, and CD127 ( Fig. 2A) . Additionally, the co-192 stimulatory molecule CD28 was expressed on approximately 50% of the Ki67 + CD8 193 T cells at days 6 and 10. When the expression of CCR7, CD45RA, CD127, and CD28 194 was analyzed simultaneously, using a Boolean gating strategy, more than 70% of the 195
Ki67
+ CD8 T cells were CCR7 -CD45RA -CD127 -CD28 +/-at day 6 after symptom 196 debut (Fig. 2B ). This phenotype was distinct from that of Ki67 -CD8 T cells at day 6 197 after infection as well as from the phenotype of CD8 T cells from uninfected controls 198 (Fig. 2B) . Furthermore, the frequency of perforin-and granzyme B-expressing cells 199 was high in total CD8 T cells during the acute phase and, then, normalized at day 60 200 (Fig. 2C) . When specifically evaluating the responding CD8 T cells, >90% co-201 expressed perforin and granzyme B at day 6 after symptom debut and at a 202 significantly higher level than non-responding CD8 T cells ( Fig. 2A and 2D) . regulatory phenotype were defined as FoxP3 + CD4 or CD8 T cells that expressed high 214 levels of CD25 and lacked expression of CD127 (Fig. 3A) . In the patients, 215
percentages of FoxP3 + CD4 T cells remained stable throughout the infection and were 216 comparable to those in uninfected controls ( Fig. 3A and 3B ). Furthermore, no 217 significant differences in absolute numbers were evident when comparing patients 218 with uninfected controls (Fig. 3C ). When analyzing CD8 T cells, no FoxP3-219 expressing cells were detected in either the patients or in the controls (data not shown). 220
We then evaluated the level of ongoing proliferation within the FoxP3 + CD4 T cell 221 subset. On average, 20% of the FoxP3 + CD4 T cells expressed Ki67 early after 222 infection ( Fig. 3D and 3E ). However, no sign of preferential proliferation was 223 observed within the FoxP3 + CD4 T cell subset, since their levels of Ki67 expression 224 were similar to those in FoxP3 -CD4 T cells ( 
Transient expression of inhibitory receptors on responding T cells during acute 230 hantavirus infection 231
Expression of inhibitory receptors is yet another mechanism to ensure T cell tolerance 232 during steady-state conditions. These receptors also regulate effector responses 233 towards pathogens. In particular, expression of inhibitory receptors has been linked to 234 and CTLA-4 on responding T cells during acute hantavirus infection. However, no 238 PD-1 was detected on CD8 T cells from hantavirus-infected patients or from the 239 uninfected controls tested here ( Fig. 4A and 4C ). On the other hand, on average 40% 240 of total CD8 T cells expressed CTLA-4 early after symptom debut ( Fig. 4B and 4D) . the patients ( Fig. 5A and 5B). Additionally, and distinct from CD8 T cells, on average 247 15% of total CD4 T cells also expressed PD-1 at day 6 after symptom debut ( Fig. 5A  248 and 5B). More than 90% of the PD-1 expressing CD4 T cells co-expressed CTLA-4 249 (Fig. 5B ). The expression of both CTLA-4 and PD-1 assessed longitudinally 250 decreased rapidly, and in the convalescent stage of disease as well as in the uninfected 251 controls, few CD4 T cells co-expressed CTLA-4 and PD-1 (Fig. 5B and 5E) . 252
Furthermore, all PD-1 + CTLA-4 + CD4 T cells showed signs of recent or ongoing 253 proliferation early after symptom debut in the infected patients (Fig. 5C) . Similarly, 254 more than 50% of the responding CD4 T cells co-expressed inhibitory PD-1 and 255 CTLA-4 (Fig. 5D ). Taken together, these results indicate the existence of cell-intrinsic 256 processes that actively balance effector T cell responses during acute viral infections. 257
These data also reveal that CD4 and CD8 T cells might utilize different inhibitory 258 receptors to modulate effector responses during an acute viral infection. 259
Discussion
261
To explore the primary human CD8 T cell response to an acute viral infection, we 262 followed a cohort of patients with acute hantavirus infection from the very first 263 presentation at the emergency clinic, only days after symptom debut, throughout the 264 acute phase of infection into the convalescent phase of disease. Our results show that 265 a primary effector CD8 T cell response developed rapidly after virus infection. The 266 response peaked within two weeks after symptoms began and, at that time, 267 encompassed up to 50% of total blood CD8 T cells and culminated in parallel with a 268 decrease in viral load and clearance of viremia in the patients. In addition, careful 269 monitoring of regulatory components did not reveal any marked induction of 270 regulatory CD4 or CD8 T cells in the patients during acute infection. Instead, CD4 271 and CD8 T cells exhibited a distinct expression pattern of inhibitory PD-1 and CTLA-272 4 early after infection. 273
From experimental models in mice, it is known that the primary effector CD8 274 T cell response during an acute viral infection includes a rapid and massive expansion 275 of activated CD8 T cells occurring during the first two weeks after infection (6, 11, 276 25) . At the peak of this response, up to 80% of all splenic CD8 T cells are specific for 277 viruses such as LCMV or VV, proliferate, and produce IFN-γ. Recent studies in 278 humans vaccinated with yellow fever virus and smallpox vaccines showed a similar 279 type of responses (1, 23). In those studies, effector CD8 T cells peaked within two 280 weeks after infection. The response encompassed up to 12.5% and 40% of CD8 T 281 cells after yellow fever virus or smallpox vaccination, respectively. In terms of time 282 and magnitude, the effector CD8 T cells that were observed early after acute 283 hantavirus infection in the present study match or even exceeds those of the earlier 284 human vaccination studies (1, 23 One limitation of the current study was the fact that we were only able to 303 assess the effector CD8 T cell response in a non antigen-specific way by combining 304 three activation markers. This strategy raises the important question as to whether Relative to this issue, we recently studied the cytomegalovirus (CMV) status of 317 patients with acute hantavirus infection (5). No evidence was found for CMV 318 reactivation during acute hantavirus infection; i.e., the number of CMV-specific CD8 319
T cells remained unchanged during the acute phase of hantavirus infection (5). This is 320 in line with findings from Miller and colleagues (23) , who showed that EBV-, CMV-, 321
and influenza-specific CD8 T cells did not contribute to the peak of the effector CD8 322 T cell response against smallpox vaccine. Albeit, similar to acute hantavirus infection 323 (35), a low-grade EBV reactivation could be detected in the smallpox vaccinated 324 individuals three weeks after vaccination (23). Thus, it still remains a possibility that 325 bystander-activated CD8 T cells contributed to the peak of the effector CD8 T cell 326 response studied here. However, we find it less likely. 327
Regulatory T cells with immunosuppressive functions, which maintain the 328 balance between protective and tissue-damaging effects of the immune response, have 329 been extensively studied in chronic and persistent viral infections of humans (12, 16) . 330
In these settings, the common notion is that regulatory T cells mitigate 331 immunopathology at the expense of decreasing the effectiveness of antigen-specific 332 early after symptom development (assessed on average day 15 after symptom debut) 344 but increased two-fold during the next three months (18). Since FoxP3 can be 345 transiently expressed in non-regulatory activated CD4 T cells (41), in the current 346 study, we used multiple phenotypic markers (FoxP3, CD25, and CD127) to ensure 347 that we were studying T cells of a regulatory phenotype. Interestingly, no CD8 T cells 348 with a regulatory phenotype were induced. In contrast, regulatory CD4 T cells readily 349 existed and represented on average 5-10% of total CD4 T cells in the infected patients. 350
Although the absolute numbers of CD4 T cells with a regulatory phenotype increased 351 slightly over time, we could not detect a specific increase of these cells occurring 352 within the first two months after symptom debut in the hantavirus-infected patients. 353
Therefore, whereas regulatory CD4 T cell numbers increased during the acute and 354 excessive immune activation (14, 15, 27) . This is particularly evident for the PD-1-363 PD-L1/2 and the CTLA-4-CD80/86 pathways, since deletion of any of these 364 molecules in mice by gene-targeting strategies causes spontaneous autoimmune 365 diseases (14, 15, 27, 31) . In humans, PD-1 and CTLA-4 have been studied primarily 366 during chronic viral infections. It has been suggested that chronically infecting 367 pathogens, such as HIV-1 and HCV, exploit these pathways for the purpose of 368 attenuating T cell immunity (3, 13, 14, 31) . We extended those studies here by 369 detecting CTLA-4 expression on a substantial fraction of responding CD4 and CD8 T 370 cells early after acute hantavirus infection. CTLA-4 expression rapidly decreased and 371
follow-up phases of West Nile and dengue virus infections (18, 20), 355
could not be detected in the infected patients at day 60 after symptom debut or in the 372 
